Title: Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents
VOLUME: 8 ISSUE: 10
Author(s):Xin Cao, Qi-Dong You, Zhi-Yu Li, Xiao-Jian Wang, Xiao-Yun Lu, Xiao-Rong Liu, Dan Xu and Bao Liu
Affiliation:Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Medicinal Chemistry,China Pharmaceutical University, No. 24, Tongjiaxiang Rd, Nanjing,210009, Jiangsu Province, P.R. China.
Keywords:Protein tyrosine kinases, Src family kinases, kinase domain, inhibitor, anticancer, drug design, SH2, SH3
Abstract: Src family of protein tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. Many SFKs inhibitors were designed and synthesized as anticancer agents in the past several years and great progress has been made. Herein, some predominant examples of SFKs inhibitors recently developed are reviewed and special attentions are paid to the most important ATP binding site inhibitors.
